SuperworthStandard Biotools profit margin LAB
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 13.6%
Standard Biotools' net margin works out at 100% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −87.8% | n/a | 49.9% |
| FY2024 | n/a | n/a | 50.1% |
| FY2023 | −70.2% | −72.0% | 47.4% |
| FY2022 | n/a | n/a | 37.8% |
| FY2021 | −45.4% | −51.7% | 53.1% |
| FY2020 | −38.4% | −36.9% | 60.3% |
| FY2019 | −55.3% | −44.2% | 54.8% |
| FY2018 | −52.2% | −42.6% | 54.6% |
| FY2017 | −59.4% | −57.3% | 51.0% |
| FY2016 | −72.8% | −70.1% | 55.9% |
| FY2015 | −46.5% | −43.7% | 59.4% |
| FY2014 | −45.4% | −44.5% | 63.2% |
| FY2013 | −23.2% | −26.2% | 71.6% |
| FY2012 | −36.4% | −34.5% | 70.7% |
| FY2011 | −52.4% | −43.3% | 69.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | n/a | |
| Q1 FY26 | 90.7% | n/a | n/a | |
| Q4 FY25 | −87.8% | n/a | n/a | |
| Q3 FY25 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q1 FY25 | n/a | n/a | n/a | |
| Q4 FY24 | n/a | n/a | n/a | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | −97.6% | −17.8 pts | n/a | |
| Q1 FY24 | −71.0% | n/a | −94.8% | |
| Q4 FY23 | −70.2% | n/a | −72.0% | |
| Q3 FY23 | −72.0% | n/a | −72.6% |
Against its peers
Companies in Drug Manufacturers - General nearest Standard Biotools' size, closest first, today.
| Company | Profit margin |
|---|---|
| LABStandard Biotools | n/m |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| LFVNLifevantage | 2.8% |
| ABUSArbutus Biopharma | 84.2% |
| SPROSpero Therapeutics | 15.7% |
| Peer median | 13.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Standard Biotools
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.